Neisseria gonorrhoeae has progressively developed resistance to many different antibiotics. Cephalosporins are the only class of drug retaining efficacy against most N. gonorrhoeae. However, decreasing sensitivity has been observed to ceftriaxone, leading to treatment failures, and raising the prospect of untreatable infections. N. gonorrhoeae is classified as “high priority” on the WHO’s priority pathogens list for R&D of new antibiotics.
The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area (BMC Infectious Diseases, 2019)